News
NVSEF
148.54
NaN%
--
Weekly Report: what happened at NVSEF last week (0511-0515)?
Weekly Report · 5d ago
Weekly Report: what happened at NVSEF last week (0504-0508)?
Weekly Report · 05/11 09:30
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Seeking Alpha · 05/08 17:25
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2026 Update
Seeking Alpha · 05/07 00:51
Weekly Report: what happened at NVSEF last week (0427-0501)?
Weekly Report · 05/04 09:30
Novartis: Revenue Lags In Q1, Outlook Unchanged
Seeking Alpha · 04/28 19:18
Earnings Snapshot: Novartis Q1 EPS and revenue trails estimates; maintains 2026 growth outlook
Seeking Alpha · 04/28 08:39
Nasdaq Futures Slip as AI Concerns Resurface, FOMC Meeting and Earnings in Focus
Barchart · 04/28 05:34
Novartis misses Q1 estimates; reaffirms FY26 guidance
Seeking Alpha · 04/28 05:34
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Seeking Alpha · 04/28 00:16
Merck: Bullish Setup Into Q1 Earnings
Seeking Alpha · 04/27 12:39
Weekly Report: what happened at NVSEF last week (0420-0424)?
Weekly Report · 04/27 09:31
Novartis pulls bid to expand Pluvicto label for prostate cancer in EU
Seeking Alpha · 04/24 15:26
Sanofi, Arrowhead, Novartis among winners of EU recommendations this week
Seeking Alpha · 04/24 15:19
WHO prequalifies Novartis’ Coartem Baby for infants
Seeking Alpha · 04/24 07:51
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
Seeking Alpha · 04/21 19:02
Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)
Seeking Alpha · 04/21 16:23
Weekly Report: what happened at NVSEF last week (0413-0417)?
Weekly Report · 04/20 09:29
Weekly Report: what happened at NVSEF last week (0406-0410)?
Weekly Report · 04/13 09:30
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Seeking Alpha · 04/13 07:28
More
Webull provides a variety of real-time NVSEF stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVSEF
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.